Navigation Links
Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
Date:11/28/2012

SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it has entered into a co-development and license agreement with Ildong Pharmaceutical Co., Ltd., for temanogrel, Arena's internally discovered inverse agonist of the serotonin 2A receptor. The agreement grants Ildong exclusive rights to commercialize temanogrel in South Korea for myocardial infarction, acute coronary syndrome, stroke, peripheral artery disease, and other cardiovascular diseases, subject to further development and regulatory approval of temanogrel. Initially, Ildong will be responsible for funding and conducting, under the direction of a joint steering committee, the next two planned clinical trials in this program: an additional Phase 1 trial in healthy volunteers and a Phase 2a proof-of-concept trial in patients.

"The Phase 1 trials Arena previously conducted support temanogrel's potential to treat a variety of conditions related to thrombosis through a novel mechanism that may provide advantages over currently available therapies," said Jack Lief, Arena's President and Chief Executive Officer. "A successful product in this category has the potential to serve as an important treatment option for many patients, and this collaboration with Ildong enables us to resume clinical development in a cost-effective manner."

Arena will maintain ownership of temanogrel outside of South Korea, and has the rights to use data generated by Ildong for the development and potential commercialization of temanogrel outside of South Korea by Arena or other Arena licensees. In addition, Ildong has agreed to pay Arena a $2 million development milestone if the planned additional Phase 1 and Phase 2a clinical trials conducted by Ildong support continued development and Arena or another Arena licensee initiates a Phase 2b clinical trial of temanogrel. Arena is also el
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
5. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
10. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
11. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
(Date:9/19/2014)... Sept. 19, 2014  Diplomat, the nation,s largest independent ... Dreyer to the Board of Directors on September ... will also serve as chair of the Audit Committee. ... of accounting, financial, compliance and operating experience in the ... served as chief financial officer, chief operating officer and ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Oct. 12 Ethicon Endo-Surgery, Inc., today ... at the 95th Annual Clinical Congress of the ... technologies of worldwide leading HARMONIC® ultrasonic and ENSEAL® ... delivery options that provide superior energy application for ...
... 12 Stereotaxis, Inc. (Nasdaq: STXS ) announced today ... Stereotaxis common stock have exercised in full their over-allotment option ... stock. The 7,475,000 shares of Stereotaxis common stock in ... option, are being sold at a price to the public ...
Cached Medicine Technology:Ethicon Endo-Surgery Unveils Full Energy Portfolio for First Time at American College of Surgeons Clinical Congress 2Ethicon Endo-Surgery Unveils Full Energy Portfolio for First Time at American College of Surgeons Clinical Congress 3Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 2Stereotaxis Announces Underwriters' Exercise of Over-Allotment Option 3
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
(Date:9/19/2014)... The Alliance for Bangladesh Worker Safety ... Fire Protection Association (NFPA), a recognized international leader ... a Memorandum of Understanding signed by both organizations, ... stakeholders with information, guidance and access to training ... safety of workers in ready-made garment (RMG) factories ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its ... health. This therapy has grown tremendously across USA in the ... safe and dependable. It has far reaching benefits for ageing ... a very healthy and active lifestyle even beyond their middle ... senior therapist at MetroMD said, “HGH or Human Growth hormones ...
(Date:9/19/2014)... September 19, 2014 "I have difficulty ... wrinkles due to stretching the skin around my eyes ... "This inspired me to design a more convenient method ... LENS SYSTEM provides a quicker, easier, more sanitary method ... to perform this task manually, saves time and effort, ...
(Date:9/19/2014)... - New research published today in the online journal ... reach 6,800 in West Africa by the end of ... , Arizona State University and Harvard University researchers ... rise in cases significantly increased in August in Liberia ... was put in place, indicating that the mass quarantine ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Research predicts possible 6,800 new Ebola cases this month 2
... North Carolina in Chapel Hill that was published in the ... two genes - C282Y and H63D, which are linked to ... increased risk of developing colon cancer. For the research, the ... which, more than 400 already had colon cancer, and were ...
... at Trinity College, Dublin, Ireland, have found from a ... arterial stiffness after smoking even one cigarette in both ... effects of smoking on large artery properties in 185 ... years. 116 non-smokers// were compared with 41 chronic smokers ...
... have traditionally been treated by removing a disc or placing ... together. Now, an artificial disc which is being studied as ... phase one study that was recently completed compared the prosthesis ... patients// were randomized, with one having a fusion operation for ...
... is being reassessed to find out if it could again ... and leprosy. The drug which is unlicensed in Europe was ... morning// sickness. However, it was banned after mothers who took ... for the Evaluation of Medicinal Products (EMEA) is now considering ...
... among children that were known until now were chickenpox, ... neurologists have found that stroke is also among one ... go unnoticed. A National Hospital's database analysis by Dr. ... California showed that four in 1000 newborns had a ...
... recent health survey across England showed that many do ... cancer and other serious diseases. The survey included nearly// ... trends were revealed by the study. ,The survey ... eating and household income. Almost 40% of women in ...
Cached Medicine News:Health News:Artificial discs available as replacements for damaged discs 2Health News:Stroke also in list of common childhood ailments 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Splint uses safe, mild to moderate force ... at the MP joints. Dorsal-based splint does ... ulnar polycentric hinges located at the MP ... malleable finger rings can be individually shaped ...
... constructed of a durable heat moldable thermoplastic for ... of the hand and fingers from stress following ... later stages of the healing process. , ... positions the wrist at 30° of flexion, the ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
Medicine Products: